AVITA’S RECELL NEARS CHINESE REGISTRATION
July 7th 2008 00:41
Thursday July 3, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: ALCHEMIA UP 12%, POLARTECHNICS DOWN 17%
* AVITA HELICON CLOSE TO CHINESE REGISTRATION
* MEDICAL THERAPIES COMPLETES MIDKINE ACQUISITION
* HUNTER HALL TAKES 10% OF BIOTA
* BAKER HEART MERGES WITH INTERNATIONAL DIABETES INSTITUTE
* BAYER LICENCES PROTEOME CROP TEST
* MINISTER CARR OPENS ARANA R&
FACILITY* AUSBIOTECH-GSK 2008 STUDENT EXCELLENCE AWARDS
* ANZ DOWN TO 19% OF OPES PRIME’S SOLAGRAN SHARES
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
AVITA, HELICON
The Chinese State Food and Drug Administration has approved the first stage of registration of Avita’s skin regeneration concept and Recell wound treatement device.
Avita (formerly Clinical Cell Culture) gave credit to Helicon for “shepherding” the product through the Chinese registration process.
The companies said importation issues needed to be resolved relating to some of the biological active components of the Recell device, including the trypsin.
Helicon chief executive officer Peter Abrahamson said the companies were “exploring all avenues to resolve the importation issues including local sourcing to enable commercialization to commence”.
Avita chief executive officer Dr William Dolphin said Helicon had excelled in “shepherding the Recell application through the highly complex Chinese State Food and Drug Administration approval and registration process.”
Recell was developed by Prof Fiona Wood and was used to treat victims of the 2002 Bali bombings.
Recell is a medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing wounds, scars and skin defects.
Avita said Recell was a stand-alone, rapid cell harvesting device that enabled surgeons to treat skin defects using the patient’s own cells collected during surgery.
Avita said Recell was better than skin grafts for accelerated healing, reduction of scarring, improved pigmentation matching and decreased stay in hospital.
Helicon said Recell had significant sales potential in China where the cosmetics and plastics markets were growing exponentially, due to an emerging middle class with disposable income.
Helicon said the amount spent in this market was $US2.4 billion a year.
Avita fell half a cent or 4.55 percent to 10.5 cents.
Helicon fell 0.1 cents or 1.54 percent to 6.4 cents
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 30 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
